Lipella Pharmaceuticals (NASDAQ:LIPO) Stock Price Up 4.2% – Still a Buy?

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) shares rose 4.2% on Monday . The stock traded as high as $0.4532 and last traded at $0.4532. Approximately 5,172 shares changed hands during trading, a decline of 99% from the average daily volume of 671,835 shares. The stock had previously closed at $0.4350.

Lipella Pharmaceuticals Price Performance

The company has a market cap of $2.09 million, a P/E ratio of -0.11 and a beta of -0.06. The company’s 50-day moving average is $0.58 and its two-hundred day moving average is $1.29.

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).